Alnylam Pharmaceuticals Leads Biopharma Charge Amid Tariff Uncertainty

Vertex, Alnylam Best Positioned as Biopharma Braces for Tariff Impact: Goldman Sachs Analyst Flags Regeneron, Biogen

A Goldman Sachs analyst has identified Vertex Pharmaceuticals and Alnylam Pharmaceuticals as the biopharma companies best positioned to weather the impact of tariffs on the industry, while warning that Regeneron Genetics Center and Biogen may be more vulnerable.

In a research note, Goldman Sachs analyst Salveen Richter highlighted the potential risks posed by tariffs on the biopharma industry, particularly for companies that rely heavily on imports. Richter noted that the tariffs could lead to increased costs, reduced profitability, and potentially even impact the availability of certain medicines.

However, Richter also identified Vertex and Alnylam as companies that are well positioned to navigate these challenges. Both companies have a strong pipeline of products that are not heavily reliant on imports, and they have also been focused on diversifying their supply chains in recent years.

In contrast, Richter flagged Regeneron and Biogen as companies that may be more vulnerable to the impact of tariffs. Both companies rely heavily on imports, particularly from China, and Richter noted that any increases in costs or tariffs could have a significant impact on their profitability.

Richter's comments come as the biopharma industry continues to grapple with the impact of tariffs and trade tensions. The industry has been vocal in its opposition to the tariffs, citing concerns about the potential impact on patients and the availability of certain medicines.

The tariffs have also sparked concerns about the potential impact on biotech research and development, as well as the ability of companies to access the raw materials and supplies they need to develop new treatments.

Overall, Richter's comments highlight the potential risks and challenges facing the biopharma industry in the wake of the tariffs, and the importance of companies having a strong pipeline of products and a diversified supply chain to navigate these challenges.